Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).
Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A. Berruti A, et al. Among authors: tagliabue e. J Natl Cancer Inst Monogr. 2011;2011(43):147-51. doi: 10.1093/jncimonographs/lgr037. J Natl Cancer Inst Monogr. 2011. PMID: 22043063
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Triulzi T, et al. Among authors: tagliabue e. Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405. Oncotarget. 2015. PMID: 26334217 Free PMC article.
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.
Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E. Triulzi T, et al. Among authors: tagliabue e. Br J Cancer. 2018 Dec;119(12):1487-1494. doi: 10.1038/s41416-018-0318-0. Epub 2018 Nov 27. Br J Cancer. 2018. PMID: 30478407 Free PMC article.
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E. Di Cosimo S, et al. Among authors: tagliabue e. Eur J Cancer. 2019 Sep;118:1-9. doi: 10.1016/j.ejca.2019.06.001. Epub 2019 Jul 5. Eur J Cancer. 2019. PMID: 31284184 Free article.
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis.
Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S. Pizzamiglio S, et al. Among authors: tagliabue e. Clin Cancer Res. 2021 Dec 1;27(23):6307-6313. doi: 10.1158/1078-0432.CCR-21-1600. Epub 2021 Sep 21. Clin Cancer Res. 2021. PMID: 34548320
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. Triulzi T, et al. Among authors: tagliabue e. Mol Oncol. 2022 Jun;16(12):2355-2366. doi: 10.1002/1878-0261.13141. Epub 2021 Dec 17. Mol Oncol. 2022. PMID: 34816585 Free PMC article.
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV. Pizzamiglio S, et al. Among authors: tagliabue e. Cancer Med. 2022 Jan;11(2):332-339. doi: 10.1002/cam4.4449. Epub 2021 Dec 17. Cancer Med. 2022. PMID: 34921525 Free PMC article. Clinical Trial.
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.
Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C. Ligorio F, et al. Among authors: tagliabue e. J Natl Cancer Inst. 2022 Dec 8;114(12):1720-1727. doi: 10.1093/jnci/djac126. J Natl Cancer Inst. 2022. PMID: 35789270
353 results